# YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey

> **NCT02224768** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 158 (actual)

## Conditions studied

- Advanced Melanoma

## Interventions

- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02224768
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2015-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02224768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02224768, "YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02224768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*